Paradoxical and bimodal immune-mediated dermatological side effects of TNF-α inhibitors: A comprehensive review

被引:1
|
作者
Behrangi, Elham [1 ,2 ]
Moodi, Farzan [3 ]
Jafarzadeh, Alireza [1 ]
Goodarzi, Azadeh [1 ,2 ,4 ]
机构
[1] Iran Univ Med Sci IUMS, Rasool Akram Med Complex Clin Res Dev Ctr RCRDC, Sch Med, Dept Dermatol, Tehran, Iran
[2] Univ Tehran Med Sci, Skin & Stem Cell Res Ctr, Tehran, Iran
[3] Iran Univ Med Sci, Sch Med, Tehran, Iran
[4] Rasool Akram Med Complex, Dept Dermatol, Niayesh St,Sattarkhan Ave, Tehran, Iran
关键词
eczema; eosinophilic cellulitis; hidradenitis supparativa; paradoxical side effects; psoriasis; sarcoidosis; TNF alpha inhibitors; ANTITUMOR-NECROSIS-FACTOR; STEVENS-JOHNSON SYNDROME; COMPLICATING ADALIMUMAB THERAPY; PYODERMA-GANGRENOSUM; RHEUMATOID-ARTHRITIS; PEMPHIGUS-VULGARIS; WELLS-SYNDROME; DOUBLE-BLIND; NEW-ONSET; ETANERCEPT;
D O I
10.1111/srt.13718
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
IntroductionDue to the increasing prevalence of immune-mediated diseases such as psoriasis, lichen planus, rheumatoid arthritis and inflammatory bowel disease, dermatologists have turned to new biologic drugs known as DMARDs (disease-modifying anti-rheumatic drugs) in recent years.Areas CoveredIn this study, we evaluate the immune-mediated dermatological side effects of DMARDS by reviewing and analyzing previous peer-reviewed research on the effects of TNF-alpha inhibitors in the treatment of skin diseases, as well as adverse effects of these drugs and some of the main causes of these effects.Expert OpinionDMARDs are very effective in improving control of the above diseases. TNF-alpha inhibitors are an important group of DMARDs that are widely used. The paradoxical adverse events (PAEs) associated with the use of TNF-alpha inhibitors are divided into three categories: true paradoxical, borderline paradoxical, and non-paradoxical. True PAEs include conditions for which TNF-alpha inhibitors are approved for treatment. Borderline PAEs are considered to occur with this class of drugs for which there is no definite approval but for which there is sufficient evidence. Although these events are rare, early recognition of the accused drug and appropriate decision-making may prevent progression of complications and irreversible side effects.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Immune-mediated oral mucosal pathology: a comprehensive review and update for clinicians Part I
    Alrashdan, Mohammad S.
    Arzmi, Mohd H.
    Kamil, Wan N. Ahmad
    Al Kawas, Sausan
    Leao, Jair C.
    [J]. ITALIAN JOURNAL OF DERMATOLOGY AND VENEREOLOGY, 2023, 158 (05) : 408 - 418
  • [32] Immune-mediated oral mucosal pathology: a comprehensive review and update for clinicians - part II
    Alrashdan, Mohammad S.
    Andreadis, Dimitrios
    Zisis, Vasileios
    Hassona, Yazan
    [J]. ITALIAN JOURNAL OF DERMATOLOGY AND VENEREOLOGY, 2024, 159 (01) : 11 - 22
  • [33] Immune checkpoint inhibitors and endocrine side effects, a narrative review
    Agrawal, L.
    Bacal, A.
    Jain, S.
    Singh, V
    Emanuele, N.
    Emanuele, Ma
    Meah, F.
    [J]. POSTGRADUATE MEDICINE, 2020, 132 (02) : 206 - 214
  • [34] Evidence-base for the beneficial effect of nutraceuticals in canine dermatological immune-mediated inflammatory diseases - A literature review
    van Amersfort, Kelly
    van der Lee, Annette
    Hagen-Plantinga, Esther
    [J]. VETERINARY DERMATOLOGY, 2023, : 266 - 283
  • [35] Inhibitors of switch kinase 'spleen tyrosine kinase' in inflammation and immune-mediated disorders: A review
    Kaur, Maninder
    Singh, Manjinder
    Silakari, Om
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2013, 67 : 434 - 446
  • [36] Treatment with PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors. Immune-mediated side effects
    Grimm, M. -O.
    Oppel-Heuchel, H.
    Foller, S.
    [J]. UROLOGE, 2018, 57 (05): : 543 - 551
  • [37] Persistence of Staphylococcus aureus colonization among individuals with immune-mediated inflammatory diseases treated with TNF-α inhibitor therapy
    Varley, Cara D.
    Deodhar, Atul A.
    Ehst, Benjamin D.
    Bakke, Antony
    Blauvelt, Andrew
    Vega, Robert
    Yamashita, Shellie
    Winthrop, Kevin L.
    [J]. RHEUMATOLOGY, 2014, 53 (02) : 332 - 337
  • [38] Side Effect Management in Immunoncology Practical Aspects in the Management of immune-mediated Side Effects under immunoncological Therapy
    Reinmuth, Niels
    Bitzer, Michael
    Deschler-Baier, Barbara
    Fischer, Juergen R.
    Kuon, Jonas
    Leipe, Jan
    Rawluk, Justyna
    Schulz, Christian
    Heussel, Claus Peter
    Schultheiss, Michael
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2019, 144 (05) : 346 - 353
  • [39] Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line
    Svedbom, Axel
    Dalen, Johan
    Black, Christopher M.
    Kachroo, Sumesh
    [J]. PATIENT PREFERENCE AND ADHERENCE, 2017, 11 : 95 - 106
  • [40] Incidence of Immune-Mediated Pseudoprogression of Lymphoma Treated with Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis
    Lee, Amy Junghyun
    Kim, Kyung Won
    Cho, Young Chul
    Ko, Yousun
    Sung, Yu Sub
    Shin, Youngbin
    Lee, Jiwoo
    Kim, Mi-hyun
    [J]. JOURNAL OF CLINICAL MEDICINE, 2021, 10 (11)